Huminsulin Basal (Nph) Kwikpen (Insulin Human)

Huminsulin Basal (Nph) Kwikpen is indicated for the long‑acting insulin needs of adults with diabetes.

• Type 1 diabetes mellitus as part of a basal‑bolus regimen.
• Type 2 diabetes mellitus when basal insulin is required.
• Adjunct therapy when oral antidiabetic agents are insufficient.
• Use during pregnancy only if benefits outweigh risks (consult healthcare provider).
• May be used in combination with rapid‑acting insulin analogues for intensive glycemic control.
• Suitable for patients who need a stable basal insulin level over 12‑24 hours.
• Can be administered subcutaneously in the abdomen, thigh, or upper arm according to injection site rotation guidelines.

• Insulin human in Huminsulin Basal (Nph) Kwikpen binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, stimulating glycogen synthesis, and suppressing hepatic gluconeogenesis. The protamine component prolongs absorption, providing a basal insulin effect lasting up to 24 hours.

Adverse reactions to Huminsulin Basal (Nph) Kwikpen are reported in clinical use and can vary in frequency, severity, and impact on daily diabetes management.

Common

• Mild hypoglycemia (blood glucose <70 mg/dL)
• Injection site redness, swelling or itching
• Lipodystrophy (localized fat tissue changes)
• Weight gain
• Transient nausea or abdominal discomfort
• Headache

Serious

• Severe hypoglycemia with loss of consciousness
• Allergic reactions such as urticaria, angioedema, or anaphylaxis
• Persistent hyperglycemia indicating insulin resistance
• Edema or heart failure exacerbation
• Insulin antibody formation leading to reduced efficacy
• Severe local infection at injection site
• Severe hypoglycemic coma requiring emergency assistance
• Life‑threatening anaphylactic shock

When prescribing or using Huminsulin Basal (Nph) Kwikpen, clinicians and patients should consider several precautionary measures to ensure safe and effective therapy.

• Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance.
• Monitor blood glucose regularly to adjust dose and avoid hypoglycemia, especially during changes in diet or activity.
• Educate patients on proper injection technique and site rotation to reduce lipodystrophy risk.
• Use caution in pregnant or breastfeeding women; benefits must outweigh potential risks.
• Review concomitant medications that may mask hypoglycemia symptoms, such as beta‑blockers.
• Store the Kwikpen at controlled room temperature and discard after the in‑use period indicated on the device.

Huminsulin Basal (Nph) Kwikpen can interact with other agents that affect glucose metabolism or insulin action; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use of other long‑acting insulins or high‑dose insulin secretagogues, which may cause severe hypoglycemia.
• MAO‑B inhibitors combined with certain oral antidiabetics that increase insulin sensitivity, raising hypoglycemia risk.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Corticosteroids, which may increase insulin requirements.
• Thiazide diuretics, which can elevate blood glucose levels.
• Alcohol, especially when consumed in excess, as it can unpredictably affect glucose control.
• ACE inhibitors, which may potentiate insulin’s antihypertensive effect but generally have low interaction risk.